Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1997 3
1998 4
2000 1
2003 1
2004 3
2006 1
2010 3
2011 3
2012 4
2013 1
2015 1
2016 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; LUNAR Investigator Group. Rovin BH, et al. Among authors: latinis k. Arthritis Rheum. 2012 Apr;64(4):1215-26. doi: 10.1002/art.34359. Epub 2012 Jan 9. Arthritis Rheum. 2012. PMID: 22231479 Free article. Clinical Trial.
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE; RIM Study Group. Oddis CV, et al. Arthritis Rheum. 2013 Feb;65(2):314-24. doi: 10.1002/art.37754. Arthritis Rheum. 2013. PMID: 23124935 Free PMC article. Clinical Trial.
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Merrill JT, et al. Among authors: latinis km. Arthritis Rheum. 2010 Jan;62(1):222-33. doi: 10.1002/art.27233. Arthritis Rheum. 2010. PMID: 20039413 Free PMC article. Clinical Trial.
14. Immunologic rheumatic disorders.
Brasington RD Jr, Kahl LE, Ranganathan P, Latinis KM, Velazquez C, Atkinson JP. Brasington RD Jr, et al. Among authors: latinis km. J Allergy Clin Immunol. 2003 Feb;111(2 Suppl):S593-601. doi: 10.1067/mai.2003.79. J Allergy Clin Immunol. 2003. PMID: 12592305 Review.
International consensus for a definition of disease flare in lupus.
Ruperto N, Hanrahan LM, Alarcón GS, Belmont HM, Brey RL, Brunetta P, Buyon JP, Costner MI, Cronin ME, Dooley MA, Filocamo G, Fiorentino D, Fortin PR, Franks AG Jr, Gilkeson G, Ginzler E, Gordon C, Grossman J, Hahn B, Isenberg DA, Kalunian KC, Petri M, Sammaritano L, Sánchez-Guerrero J, Sontheimer RD, Strand V, Urowitz M, von Feldt JM, Werth VP, Merrill JT; Lupus Foundation of America, Inc. International Flare Consensus Initiative. Ruperto N, et al. Lupus. 2011 Apr;20(5):453-62. doi: 10.1177/0961203310388445. Epub 2010 Dec 10. Lupus. 2011. PMID: 21148601
Phase II trial of methotrexate in myasthenia gravis.
Pasnoor M, He J, Herbelin L, Dimachkie M, Barohn RJ; Muscle Study Group. Pasnoor M, et al. Ann N Y Acad Sci. 2012 Dec;1275(1):23-8. doi: 10.1111/j.1749-6632.2012.06804.x. Ann N Y Acad Sci. 2012. PMID: 23278574 Free PMC article. Clinical Trial.
26 results